Second medical use or indication claims
|
|
- Meredith Gardner
- 5 years ago
- Views:
Transcription
1 Question Q238 National Group: Title: Contributors: Reporter within Working Committee: AUSTRIA Second medical use or indication claims Marc KESCHMANN Marc KESCHMANN Date: May 12, 2014 Questions I. Current law and practice Groups are invited to answer the following questions under their national laws. If those national and regional laws apply to a set of questions, please answer the questions separately for each set of laws. Please number your answers with the same numbers used for the corresponding questions. 1) Does your country permit patents covering any aspect of new uses of known pharmaceutical compounds (hereafter referred to as second medical use claims)? If yes, please answer Questions 2) to 7) inclusive before proceeding to the questions in Parts I and II. If no, please proceed directly to the questions in Parts II and III. 2) If the answer to Question 1) is yes, please answer the following sub questions. a) What is the basis for patent protection? Para. 3 Sec 3 of the Austrian Patent Act b) What types of second medical use are patentable? See, for example, paragraphs 14) - 17) above/wgls. All types mentioned in paragraphs 14) - 17) of the WGLs c) Are any types of second medical use impermissible subject matter? See, for example, paragraphs 14) - 17) above/wgls. No. d) What forms of second medical use claims are permissible? See, for example, paragraphs 26) - 33) above/wgls. 1
2 Swiss-type claim format 'purpose-limited' product claim format ('Substance X for use in the treatment of condition Y) e) What forms of second medical use claims are not permissible? See, for example, paragraphs 26) - 33) above/wgls. Use claim ('Use of compound X for treatment of disease Y') however, undecided. Method of treatment f) Has any guidance been provided by courts or the national patent office in relation to the meaning, scope and/or effect of 'treatment', 'treating' or 'use to treat' integers in second medical use claims? See, for example, paragraphs 34) - 39) above WGLs. Yes - The Supreme Court (OGH) in the Isoflavon -case (17Ob35/09k, GRUR Int 2010,1080) elucidated that second medical use claims (in this case a Swiss type claim) are only infringed if it has been shown that the intended purpose of the invention, i.e. the medical treatment, is indeed achieved to a substantial extent. 3) If your country permits second medical use claims: a) Who may be liable for infringement of such claims? For example: i) the party marketing the drug with label instructions which describe the patented use; ii) the physician prescribing the drug for such use; There is no case law in Austria. iii) the pharmacist dispensing a drug for such purpose; Yes (in case of a 'purpose-limited' product claim format). iv) the patient using the drug for such purpose? No this falls under the exemption of private use. b) Are any parties exempt from infringement or liability for infringement of such claims. If so, what classes of party? Only privately acting parties are exempt from infringement or liability for infringement. Medical doctors are not considered acting privately when exercising their profession. Otherwise, no class of party is generally exempt from infringement or liability for infringement. However, the Bolar exemption applies. c) Are such claims enforceable on the basis of direct or indirect infringement? Please provide details. 2
3 The claims may be enforceable both, on the basis of direct and indirect infringement. Direct infringement would be the case, if a generics company produces, offers or sells a drug for the patented indication (e.g. by including the indication in the product information leaflet). Indirect infringement would have to be affirmed in a case as described below under question 4. 4) If a drug is approved for more than one indication, one or more of which (but not all) falls within the claims of a patent, is it an infringement if a party makes, supplies or uses a generic version of the drug for any use? In case the patented indication is mentioned in the product information leaflet (onlabel use), the act of making and supplying constitutes a direct infringement. In case the patented indication is not specifically mentioned in the product information leaflet (off-label use), indirect infringement could be affirmed provided that the supplier knows or it is obvious in the circumstances, that the drug will be prescribed and/or used by the patient for the patented indication. 5) If the answer to Question 4) is yes, please answer the following sub questions in that context. a) Is each of the acts of making, supplying and using a form of infringement? If not, please specify which (or any other) acts which constitute infringement. The acts of making, offering, supplying and using as well as the acts of importing and holding for the aforementioned purposes constitute direct infringement. Only the acts of offering and supplying constitute indirect infringement. b) Is it necessary for a finding of infringement that the party making, supplying or using the generic version of the drug does so in connection with the infringing use? c) If yes to b), is it necessary that the party knows that their actions are in connection with the infringing use? d) If yes to c), what standard of knowledge is required? See, for example, paragraphs 38) and 47) above. Positive knowledge of the infringement or the infringement is obvious from the circumstances. 6) How do the courts determine infringement of a second medical use claim? What are the legal tests and evidentiary requirements? According to the Austrian group s knowledge, in all pertinent court cases the Court determined infringement of a second medical use claim on basis of information found 3
4 in the product information leaflet - such as Isoflavon - decision (17Ob35/09k, GRUR Int 2010,1080) 7) What relief is available for infringement of a second medical use claim: a) at a preliminary / interim / interlocutory level? Interim injunction b) by way of final relief? Injunction, damages, delivery up/destruction, publication of judgment, order to provide information about origin and delivery, account of profits 8) In respect of Question 7)a), can a preliminary / interim / interlocutory injunction be granted solely upon the statements provided in the product packaging or based on the writing of a prescription? If not, what is the basis for relief? No, there are no interim injunction restrictions that are specific to second medical use claims. 9) In respect of Question 7)b), what level of proof is required to obtain a final injunction? see question 5d) 4
5 II. Policy considerations and proposals for improvements to your current law 10) If your country permits second medical use claims, please answer the following sub questions. a) What are the policy reasons behind permitting such claims? Adequate protection of pharmaceutical research and development b) Are such claims as are currently permissible in your country considered to strike the right balance between the interests of relevant stakeholders? c) Is it considered that such claims better serve the interests of some stakeholders and/or are detrimental to other stakeholders? No. d) If there is any empirical or anecdotal data available, please address the following. N/A i) What is the prevalence of second medical use claims in your country? ii) What is the profile of patentees for second medical use claims in your country? 11) If your country does not permit second medical use claims, please answer the following sub questions. a) What are the policy reasons behind not permitting such claims? b) Would such claims serve the interests of relevant stakeholders? c) Would such claims be considered to better serve the interests of some stakeholders and/or be detrimental to other stakeholders? 12) To what extent does your country's law in relation to second medical use claims affect the pharmaceutical industry (originator and generic) in your country? III. Proposals for harmonisation The Groups are invited to put forward proposals for the adoption of harmonised laws in relation to second medical use claims. More specifically, the Groups are invited to answer the following questions without regard to their existing national laws. 13) Is it desirable to permit second medical use claims? 14) Is harmonisation of laws relating to second medical use claims desirable? 5
6 15) Please provide a standard that you consider to be best in each of the following areas relating to second medical use claims. a) Types of second medical use constituting permissible subject matter. See, for example, paragraphs 14) - 17) above/wgls. All types mentioned in paragraphs 14) - 17) of the WGLs b) Types of any second medical use constituting impermissible subject matter. See, for example, paragraphs 14) - 17) above/wgls. None c) Form of permissible claims. See, for example, paragraphs 26) - 33) above/wgls. 'purpose-limited' product claim d) Form of impermissible claims. See, for example, paragraphs 26) - 33) above/wgls. Claims referring to a method of treatment e) Who may be liable for infringement? Any entity not acting privately, such as a patient. f) Any parties/institutions that should be exempted from infringement or liability for infringement. No g) Where a drug is approved for more than one indication, one or more of which (but not all) falls within the claims of a patent, the acts that should constitute patent infringement, and in particular, the standard of knowledge of the alleged infringer. When mentioned the patented indication in the product information leaflet, at least the acts of making, offering and supplying should constitute a direct infringement. In case the patented indication is not specifically mentioned in the product information leaflet (off-label use), indirect infringement should be affirmed in case the supplier knows or it is obvious in the circumstances, that the drug is prescribed and/or used for the patented indication. h) Relief available upon a finding of infringement: i) at a preliminary / interim / interlocutory level; and Interim injunction ii) by way of permanent relief. Injunction, damages, delivery up/destruction, publication of judgment, order to provide information about origin and delivery, account of profits i) In each case for h)i) and h)ii), the level of proof for the granting of such relief. 6
7 Zusammenfassung: Die österreichische Landesgruppe ist der Auffassung, dass Patentansprüche betreffend eine zweite medizinische Indikation hauptsächlich in der Form des zweckgerichteten Stoffanspruchs zur Verfügung stehen sollte. Hinsichtlich der Haftung für Verletzungshandlungen sollte es keine speziellen Ausnahmen geben (mit Ausnahme der Bolar Regel). Lediglich im privaten Bereich sollte die Verwendung der patentierten Indikation keine Patentverletzung darstellen, wie dies auch bei jedem anderen Erfindungsgegenstand der Fall ist. Das Herstellen, Anbieten, in Verkehr bringen und Gebrauchen sowie das Importieren und Besitzen für die genannte Zwecke sollten eine unmittelbare Verletzung darstellen. Im Zusammenhang mit der off-label Verwendung sollte eine wirksame Durchsetzung der Patentrechte im Wege der mittelbaren Verletzung gewährleistet sein. Summary The Austrian Group is of the opinion that second medical use claims should mainly be available in the 'purpose-limited' product claim format ('Substance X for use in the treatment of condition Y). There should not be any special exemption from liability for infringement of such claims (except of the Bolar exemption). Only privately acting parties should be exempt from infringement or liability for infringement as is the case with any other patented subject matter. The acts of making, offering, supplying and using as well as the acts of importing and holding for the aforementioned purposes should constitute direct infringement. Indirect infringement should be available in particular in connection with off-label use in order to secure efficient patent enforcement. Résumée Le Groupe Autrichien est d'avis que les revendications relatives à une deuxième indication médicale devraient être principalement sous la forme de revendication dans le format "substance X pour utilisation dans le traitement de la maladie Y. Responsabilité à l'égard des actes de contrefaçon il devrait y avoir aucune exception spéciaux (à l'exception de la règle Bolar). Seulement dans le secteur privé, l'utilisation de l'indication brevetée ne doit pas constituer une contrefaçon, comme c'est le cas avec tout autre objet invention. La production, l offre, la mise sur le marché et l'utilisation ainsi que l'importation et la possession aux fins ci-dessus devrait constituer une contrefaçon direct. Dans le cadre de l'utilisation offlabel d'une application effective des droits de brevet doit être garantie par voie de contrefaçon indirecte. 7
No. According to the PTO s internal examination guidelines, second medical use claims are not patentable.
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: Argentina Second medical use or indication claims Gastón RICHELET, Ricardo D. RICHELET Gastón RICHELET Date: May 19,
More informationSecond medical use or indication claims
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: Bulgarian National Group Second medical use or indication claims Valentina NESHEVA Valentina NESHEVA Date: 16 May 2014
More informationSecond medical use or indication claims
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: Egyptian National Group Second medical use or indication claims Eman MOHEY, Gamal ABOU ALI Ahmed ABOU ALI Date: May
More informationSecond medical use or indication claims. [Please insert name last name in CAPITAL letters please]
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: New Zealand Second medical use or indication claims Michael BROWN, Partner Helen BELLCHAMBERS, Associate A J Park [Please
More informationSecond medical use or indication claims. Winnie Tham, Edmund Kok, Nicholas Ong
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: AIPPI SINGAPORE Second medical use or indication claims Winnie Tham, Edmund Kok, Nicholas Ong THAM, Winnie Date: 17
More informationSecond medical use or indication claims. Mr. Antonio Ray ORTIGUERA Angara Abello Concepcion Regala & Cruz Law Offices Philippines
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: PHILIPPINES Second medical use or indication claims Mr. Alex Ferdinand FIDER Mr. Antonio Ray ORTIGUERA Angara Abello
More informationLiability for contributory infringement of IPRs certain aspects of patent infringement
Question Q204P National Group: AIPPI PANAMA GROUP Title: Liability for contributory infringement of IPRs certain aspects of patent infringement Contributors: Julie Martinelli Representative within Working
More informationHungary Hongrie Ungarn. Report Q204
Hungary Hongrie Ungarn Report Q204 in the name of the Hungarian Group by Marcell KERESZTY, András ANTALFFY-ZSÍROS, Judit KERÉNY, Katalin MÉSZÁROS, Imre MOLNÁR, Tivadar PALÁGYI and Zsolt SZENTPÉTERI Liability
More informationSweden Suède Schweden. Report Q202
Sweden Suède Schweden Report Q202 in the name of the Swedish Group by Fredrik CARLSSON, Ivan HJERTMAN, Bo JOHANSSON, Birgitta LARSSON, Hampus RYSTEDT, Louise WALLIN, Claudia WALLMAN and Johan ÖBERG The
More informationSecond medical use or indication claims
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: Canada Second medical use or indication claims Matthew ZISCHKA Santosh CHARI Carol HITCHMANN Roseanne CALDWELL Charles
More informationThe availability of injunctions in cases of infringement of IPRs
Question Q219 National Group: Austria Title: The availability of injunctions in cases of infringement of IPRs Contributors: Reporter within Working Committee: Peter Pawloy, Christian Gassauer-Fleissner
More informationThe use of prosecution history in post-grant patent proceedings
Question Q229 National Group: Hungary Title: The use of prosecution history in post-grant patent proceedings Contributors: Dr. Marcell KERESZTY (Head of the Working Committee), Dr. Daisy MACHYTKA-FRANK,
More informationSwitzerland Suisse Schweiz. Report Q193
Switzerland Suisse Schweiz Report Q193 in the name of the Swiss Group by Andrea CARREIRA, Jan D HAEMER, Andri HESS, Paul PLISKA, Michael STÖRZBACH and Marco ZARDI Divisional, Continuation and Continuation
More informationJapan Japon Japan. Report Q189. in the name of the Japanese Group
Japan Japon Japan Report Q189 in the name of the Japanese Group Amendment of patent claims after grant (in court and administrative proceedings, including re examination proceedings requested by third
More informationDr. Daisy MACHYTKA-FRANK Dr. Lászlóné CSUTORÁS Imre MOLNÁR Miklós TAR Dr. Zoltán KOVÁRI Zsolt SZENTPÉTERI
Question Q238 National Group: Title: Contributors: Reporter within Working Committee: Hungarian AIPPI Group Second medical use or indication claims Dr. Éva SOMFAI Dr. Daisy MACHYTKA-FRANK Dr. Lászlóné
More informationPoland Pologne Polen. Report Q193. in the name of the Polish Group by Agnieszka JAKOBSCHE and Katarzyna KARCZ
Poland Pologne Polen Report Q193 in the name of the Polish Group by Agnieszka JAKOBSCHE and Katarzyna KARCZ Divisional, Continuation and Continuation in Part Patent Applications Questions I) Analysis of
More informationLiability for contributory infringement of IPRs certain aspects of patent infringement
Question Q204P National Group: Sweden Title: Liability for contributory infringement of IPRs certain aspects of patent infringement Contributors: Mathilda ANDERSSON, Erik FICKS, Dag HEDEFÄLT and Martin
More informationLiability for contributory infringement of IPRs certain aspects of patent infringement
Question Q204P National Group: The Danish Group Title: Liability for contributory infringement of IPRs certain aspects of patent infringement Contributors: Sture Rygaard, Anders Valentin, Emil Jurcenoks,
More informationArgentina Argentine Argentinien. Report Q193. in the name of the Argentinian Group
Argentina Argentine Argentinien Report Q193 in the name of the Argentinian Group Divisional, Continuation and Continuation in Part Patent Applications Questions I) Analysis of the current law 1) Are divisional,
More informationInventorship of Multinational Inventions (Q 244)
Die Seite der AIPPI La page de l AIPPI Inventorship of Multinational Inventions (Q 244) REPORT OF SWISS GROUP * Questions I. Current law and practice 1. Please describe your law defining inventorship and
More informationDenmark Danemark Dänemark. Report Q193. in the name of the Danish Group by Ejvind CHRISTIANSEN, Torsten NØRGAARD and Holm SCHWARZE
Denmark Danemark Dänemark Report Q193 in the name of the Danish Group by Ejvind CHRISTIANSEN, Torsten NØRGAARD and Holm SCHWARZE Divisional, Continuation and Continuation in Part Patent Applications Questions
More informationPatentable Subject Matter and Medical Use Claims in the Pharmaceutical Sector
Patentable Subject Matter and Medical Use Claims in the Pharmaceutical Sector 2012 LIDC Congress, Prague, 12 October 2012 Dr. Simon Holzer, Attorney-at-Law, Partner 3 October 2012 2 Introduction! Conflicting
More informationFaculty of Law Roman Law
Roman Law The why and how of an anachronism 13.10.17 joseluis.alonso@rwi.uzh.ch Page 1 An Example: The Accessory Nature of Real Securities Pledge & Hypothec Real Securities (vs. 'personal' securities)
More informationABPI Associação Brasileira da Propriedade Intelectual (Brazil) Liability for contributory infringement of IPRs certain aspects of patent infringement
Question Q204P National Group: ABPI Associação Brasileira da Propriedade Intelectual (Brazil) Title: Liability for contributory infringement of IPRs certain aspects of patent infringement Contributors:
More informationSouth Africa Afrique du Sud Südafrika. Report Q189. in the name of the South African Group by Hans H. HAHN, Janusz LUTEREK and HUGH MOUBRAY
South Africa Afrique du Sud Südafrika Report Q189 in the name of the South African Group by Hans H. HAHN, Janusz LUTEREK and HUGH MOUBRAY Amendment of patent claims after grant (in court and administrative
More informationPregabalin: Where stand plausibility, Swiss-form claims, late amendment and more?
University College London IBIL Innovation Seminar 2018 Pregabalin: Where stand plausibility, Swiss-form claims, late amendment and more? Dr. Matthias Zigann Presiding Judge Regional Court Munich I Swiss
More informationWorking Guidelines Q238. Second medical use and other second indication claims
Working Guidelines by Thierry CALAME, Reporter General Sarah MATHESON and John OSHA, Deputy Reporters General Anne Marie VERSCHUR, Sara ULFSDOTTER and Kazuhiko YOSHIDA Assistants to the Reporter General
More informationSWISS FEDERAL INSTITUTE OF INTELLECTUAL PROPERTY
PCT Applicant s Guide National Phase National Chapter Page 1 SWISS FEDERAL INSTITUTE OF INTELLECTUAL PROPERTY AS DESIGNATED (OR ELECTED) OFFICE CONTENTS THE ENTRY INTO THE NATIONAL PHASE SUMMARY THE PROCEDURE
More informationBAYER CROPSCIENCE LP v. THE ATTORNEY GENERAL OF CANADA, AND THE COMMISSIONER OF PATENTS
[Abstract prepared by the PCT Legal Division (PCT-2018-0002)] Case Name: BAYER CROPSCIENCE LP v. THE ATTORNEY GENERAL OF CANADA, AND THE COMMISSIONER OF PATENTS Jurisdiction: FEDERAL COURT OF APPEAL (CANADA)
More informationInjunctions in cases of infringement of IPRs
Question Q219 National Group: Hungary Title: Injunctions in cases of infringement of IPRs Contributors: Dr. Gusztáv Bacher, Dr. Gábor Faludi, Dr. Katalin Horváth, Dr. Zsófia Klauber, Imre Molnár, János
More informationBrazil Brésil Brasilien. Report Q205
Brazil Brésil Brasilien Report Q205 in the name of the Brazilian Group by Carlos EDSON STRASBURG, Cláudio Roberto BARBOSA, Cristina PALMER, Gabriela NEVES, Maitê Cecilia FABBRI MORO and Marc EHLERS Exhaustion
More informationPoland Pologne Polen. Report Q205. in the name of the Polish Group by Katarzyna KARCZ, Jaromir PIWOWAR, Tomasz RYCHLICKI
Poland Pologne Polen Report Q205 in the name of the Polish Group by Katarzyna KARCZ, Jaromir PIWOWAR, Tomasz RYCHLICKI Exhaustion of IPRs in cases of recycling and repair of goods Questions I) Analysis
More informationTHE HONOURABLE MR. JUSTICE KELEN LETWLED KASAHUN TESSMA (AYELE) - and - THE MINISTER OF CITIZENSHIP AND IMMIGRATION REASONS FOR ORDER AND ORDER
Date: 20031002 Docket: IMM-5652-02 Citation: 2003 FC 1126 Ottawa, Ontario, this 2 nd day of October, 2003 Present: THE HONOURABLE MR. JUSTICE KELEN BETWEEN: LETWLED KASAHUN TESSMA (AYELE) Applicant - and
More informationConstruction of second medical use claims. The Hon. Mr Justice Richard Arnold
Construction of second medical use claims The Hon. Mr Justice Richard Arnold The problem Claim 1 of European Patent (UK) No. 0 934 061 reads: Use of [pregabalin] or a pharmaceutically acceptable salt thereof
More informationDivisional, Continuation and Continuation-in-Part Applications (Q 193)
Die Seite der AIPPI / La page de l AIPPI Divisional, Continuation and Continuation-in-Part Applications (Q 193) REPORT OF SWISS GROUP * Die Schweizer Gruppe sieht mehrere Vorteile für den Anmelder und
More informationJapan Japon Japan. Report Q194. in the name of the Japanese Group by Eiichiro KUBOTA
Japan Japon Japan Report Q194 in the name of the Japanese Group by Eiichiro KUBOTA The Impact of Co Ownership of Intellectual Property Rights on their Exploitation Questions I) The current substantive
More informationWorking Guidelines. Question Q209. Selection Inventions the Inventive Step Requirement, other Patentability Criteria and Scope of Protection
Working Guidelines by Jochen E. BÜHLING, Reporter General Dariusz SZLEPER and Thierry CALAME, Deputy Reporters General Nicolai LINDGREEN, Nicola DAGG and Shoichi OKUYAMA Assistants to the Reporter General
More informationQuestionnaire on Exceptions and Limitations to Patent Rights. The answers to this questionnaire have been provided on behalf of:
The answers to this questionnaire have been provided on behalf of: Country: Austria... Office: Austrian Patent Office (APO)... Person to be contacted: Name:... Title:... E-mail:... Telephone:... Facsimile:...
More informationBelgium Belgique Belgien. Report Q193. in the name of the Belgian Group by Nele D HALLEWEYN
Belgium Belgique Belgien Report Q193 in the name of the Belgian Group by Nele D HALLEWEYN Divisional, Continuation and Continuation in Part Patent Applications Preliminary comments The answers to Q193
More informationCanada Canada Kanada. Report Q193. in the name of the Canadian Group by France COTE, Alfred A. MACCHIONE and Michel SOFIA
Canada Canada Kanada Report Q193 in the name of the Canadian Group by France COTE, Alfred A. MACCHIONE and Michel SOFIA Divisional, Continuation and Continuation in Part Patent Applications Questions I)
More informationFederal Court Reports Dutch Industries Ltd. v. Canada (Commissioner of Patents) (T.D.) [2002] 1 F.C. 325
Page 1 of 11 Source: http://decisions.fct-cf.gc.ca/en/2001/2001fct879/2001fct879.html Federal Court Reports Dutch Industries Ltd. v. Canada (Commissioner of Patents) (T.D.) [2002] 1 F.C. 325 Date: 20010813
More informationFinland Finlande Finnland. Report Q210
Finland Finlande Finnland Report Q210 in the name of the Finnish Group by Minna AALTO SETÄLÄ, Anette ALÉN, Marjut ALHONNORO, Heikki HALILA, Jussi KARTTUNEN, Kai KUOHUVA, Petri RINKINEN, Panu SIITONEN and
More informationCanada Canada Kanada. Report Q187. in the name of the Canadian Group by Steven B. GARLAND (Chairman) and Colin INGRAM
Canada Canada Kanada Report Q187 in the name of the Canadian Group by Steven B. GARLAND (Chairman) and Colin INGRAM Limitations on exclusive IP Rights by competition law Questions I) STATE OF THE SUBSTANTIVE
More informationSecond Medical Use Patents in Europe: Are the UK and Germany Swapping Approaches?
WHITE PAPER January 2019 Second Medical Use Patents in Europe: Are the UK and Germany Swapping Approaches? The UK Supreme Court s ruling in Warner Lambert v Actavis resulted from deliberations over the
More informationSeventh Supplement dated 6 May to the Euro Medium Term Note Programme Base Prospectus dated 5 June 2014 BNP PARIBAS. (incorporated in France)
Seventh Supplement dated 6 May 2015 to the Euro Medium Term Note Programme Base Prospectus dated 5 June 2014 BNP PARIBAS (incorporated in France) (as Issuer) 90,000,000,000 EURO MEDIUM TERM NOTE PROGRAMME
More informationThe patentability criteria for inventive step / non-obviousness
Question Q217 National Group: Title: Sweden/Suède/Schweden The patentability criteria for inventive step / non-obviousness Contributors: Lars BJÖRKLUND, Magnus DAHLMAN, Heléne ELIASSON, Kristian FREDRIKSON,
More informationRegional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities
REPUBLIC OF SOUTH AFRICA Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities Topic 13: The Effective Administrative Process for the Grant
More information: Liability for contributory infringement of IPRs certain aspects of patent infringement
Question Q204P National Group : AIPPI Indonesia Title : Liability for contributory infringement of IPRs certain aspects of patent infringement Contributors : Migni Myriasandra Representative within Working
More informationMinutes of SSP Minute du PPU
Présence Attendance Date : 2013/05/08 See Attendance document Voir document de présence Sujets abordés Worked subjects Presentation : Stephen Woodley (see document in annexe A voir document en annexe A)
More informationThe Relevance of Traditional Knowledge to Intellectual Property Law. Katja GRABIENSKI, Martina SCHUSTER, THORSTEN BAUSCH, Jan DOMBROWSKI
Question Q232 National Group: German Group Title: The Relevance of Traditional Knowledge to Intellectual Property Law Contributors: Katja GRABIENSKI, Martina SCHUSTER, THORSTEN BAUSCH, Jan DOMBROWSKI Reporter
More informationCybercrime Convention Implementation into Swiss Law
10.04.2009 1 Cybercrime Convention Implementation into Swiss Law From: Dr. Christa Stamm-Pfister, VISCHER For: SwiNOG-18, 2. April 2009, Bern 10.04.2009 2 Overview Cybercrime Convention Legislative Procedure
More informationH. R To amend the Federal Food, Drug, and Cosmetic Act with respect to compounding pharmacies, and for other purposes.
I 11TH CONGRESS 1ST SESSION H. R. 21 To amend the Federal Food, Drug, and Cosmetic Act with respect to compounding pharmacies, and for other purposes. IN THE HOUSE OF REPRESENTATIVES JUNE 12, 201 Mr. GRIFFITH
More informationThe use of prosecution history in post-grant patent proceedings. Jochen EHLERS, LL.M.
Question Q229 National Group: German Group Title: The use of prosecution history in post-grant patent proceedings Contributors: Dietmar HAUG, LL.M. Dr. Ralph NACK Jochen EHLERS, LL.M. Dr. Tim MEYER-DULHEUER,
More informationFaculty of Law Roman Law
Roman Law The why and how of an anachronism 15/10/18 joseluis.alonso@rwi.uzh.ch Page 1 Justinian and the Corpus Iuris (530 CE) The Digest and the classical jurisprudence (1st-3rd cent. CE) The Codex and
More informationDecision of the Dispute Resolution Chamber
Decision of the Dispute Resolution Chamber passed in Zurich, Switzerland, on 13 August 2015, in the following composition: Geoff Thompson (England), Chairman Jon Newman (USA), member Mario Gallavotti (Italy),
More informationThe Third Amendment to the Patent Law of China. On December 27, 2008, the Standing Committee of the National People's
The Third Amendment to the Patent Law of China On December 27, 2008, the Standing Committee of the National People's Congress adopted the third amendment to the Patent Law of the People's Republic of China,
More informationYoung EPLAW Congress. Bolar provision: a European tour. Brussels, 27 April 2015 Guillaume Bensussan Kathy Osgerby Agathe Michel de Cazotte
Young EPLAW Congress Bolar provision: a European tour Brussels, 27 April 2015 Guillaume Bensussan Kathy Osgerby Agathe Michel de Cazotte Introduction Bolar provision: a European tour Part 1 UK A) Recent
More informationStanding Committee on Access to Information, Privacy and Ethics
Standing Committee on Access to Information, Privacy and Ethics ETHI NUMBER 031 2nd SESSION 41st PARLIAMENT EVIDENCE Wednesday, February 4, 2015 Chair Mr. Pierre-Luc Dusseault 1 Standing Committee on
More informationDenmark Danemark Dänemark. Report Q192. in the name of the Danish Group by Dorte WAHL and Martin Sick NIELSEN
Denmark Danemark Dänemark Report Q192 in the name of the Danish Group by Dorte WAHL and Martin Sick NIELSEN Acquiescence (tolerance) to infringement of Intellectual Property Rights Questions 1) The Groups
More informationBE IT RESOLVED AS A SPECIAL RESOLUTION THAT:
SPECIAL RESOLUTION OF MEMBERS Continuing the Corporation under the provisions of the Canada Not- for- profit Corporations Actand authorizing the directors to apply for a Certificate of Continuance. WHEREAS
More informationUnited States of America Etats-Unis d Amérique Vereinigte Staaten von Amerika. Report Q186
United States of America Etats-Unis d Amérique Vereinigte Staaten von Amerika Report Q186 in the name of the United States Group by Michael KIRK, Chad J. DOELLINGER and James CROWNE Punitive damages as
More informationMINUTES. of the. Tenth Ordinary General Meeting of Shareholders. TEMENOS Group AG ( Company )
MINUTES of the Tenth Ordinary General Meeting of Shareholders of TEMENOS Group AG ( Company ) held on 17 th June 2011, at 3:00 p.m., at Le Restaurant du Parc des Eaux-Vives, 82 quai Gustave-Ador, 1211
More informationUNITED KINGDOM ROYAUME-UNI VEREINIGTES KÖNIGREICH REPORT QUESTION Q204P
UNITED KINGDOM ROYAUME-UNI VEREINIGTES KÖNIGREICH REPORT QUESTION Q204P National Group: UK Title: Liability for contributory infringement of IPRs certain aspects of patent infringement Contributors: Representative
More informationVorlesung / Course Introduction to Comparative Law and Unification of Law Einführung in die Rechtsvergleichung und Rechtsvereinheitlichung
Prof. Dr. Alexander Trunk Vorlesung / Course Introduction to Comparative Law and Unification of Law Einführung in die Rechtsvergleichung und Rechtsvereinheitlichung Summer term 2018 http://www.eastlaw.uni-kiel.de
More informationPatent Act, B.E (1979) As Amended until Patent Act (No.3), B.E (1999) Translation
Patent Act, B.E. 2522 (1979) As Amended until Patent Act (No.3), B.E. 2542 (1999) Translation BHUMIBOL ADULYADEJ, REX. Given on the 11th day of March, B.E. 2522; Being the 34th year of the present Reign
More informationInjunctions in cases of infringement of IPRs. The Groups are invited to answer the following questions under their national laws:
Question Q219 National Group: Title: Contributors: Reporter within Working Committee: Date: Ireland Injunctions in cases of infringement of IPRs Gerard KELLY [please insert name] [please insert date]]
More information2017 Georgia New Pharmacy/Medical Legislative Activity. Revised,
2017 Georgia New Pharmacy/Medical Legislative Activity Revised, 2.12.2017 This document provides a summary of key points regarding each individual piece of legislation. Readers are to full current versions
More informationThe use of prosecution history in post-grant patent proceedings
SPAIN Question Q229 Title: Spanish Group: The use of prosecution history in post-grant patent proceedings Antonio Castán (President) Alicia Arroyo Isidro José García Egea Patricia Koch Jorge Llevat Manuel
More informationICC Electronic data approaches Senegal
ICC Electronic data approaches Senegal ASP.net's user name Submitted on Language BCFP_SN 4/1/2016 6:58:34 PM fr-fr 1. I.1 Is the notification document available in electronic form in your country? 2. I.2
More informationPRESCRIPTION MONITORING PROGRAM MODEL ACT 2010 Revision
PRESCRIPTION MONITORING PROGRAM MODEL ACT 2010 Revision Section 1. Short Title. This Act shall be known and may be cited as the Prescription Monitoring Program Model Act. Section 2. Legislative Findings
More informationContact Person. Address nam. SNP 33 Postal Code
Bonjour, Une nouvelle réponse a été soumise pour votre questionnaire 'Rapport national relatif à la mise en œuvre de la Convention de la Haye de 1954 et ses deux Protocoles de 1954 et 1999'. Cliquer sur
More informationNotwithstanding Article 29, any invention that is liable to injure public order, morality or public health shall not be patented (Article 32).
Japan Patent Office (JPO) Contents Section 1: General... 1 Section 2: Private and/or non-commercial use... 2 Section 3: Experimental use and/or scientific research... 3 Section 4: Preparation of medicines...
More informationSOUTH AFRICAN NATIONAL STANDARD
ISBN 978-0-626-34347-7 IEC 60439-5:2006 SOUTH AFRICAN NATIONAL STANDARD Low-voltage switchgear and controlgear assemblies Part 5: Particular requirements for assemblies This national standard is the identical
More informationDamages for the Injuring or Killing of an Animal in Swiss Law
Damages for the Injuring or Killing of an Animal in Swiss Law By Dr. Eveline Schneider Kayasseh 1 I. Introduction On 1 April 2003, after perennial preparatory work and heated public debates, new provisions
More informationStanding Committee on Public Safety and National Security
Standing Committee on Public Safety and National Security SECU NUMBER 055 1st SESSION 42nd PARLIAMENT EVIDENCE Monday, March 6, 2017 Chair Mr. Robert Oliphant 1 Standing Committee on Public Safety and
More informationSITUATION EN CÔTE D IVOIRE AFFAIRE LE PROCUREUR c. LAURENT GBAGBO ANNEXE 3 PUBLIQUE EXPURGÉE
ICC-02/11-01/11-647-Anx3-Red 16-05-2014 1/9 NM PT SITUATION EN CÔTE D IVOIRE AFFAIRE LE PROCUREUR c. LAURENT GBAGBO ANNEXE 3 PUBLIQUE EXPURGÉE Tableau recensant les erreurs commises par la victimes lorsqu
More informationAUSTRIA: 20 YEARS IN THE EU
Flash Eurobarometer 407 AUSTRIA: 20 YEARS IN THE EU NATIONAL REPORT Fieldwork: November-December 2014 Publication: January 2015 This survey has been requested by the European Commission, Directorate-General
More informationBenin Tourist visa Application
Benin Tourist visa Application Please enter your contact information Name: Email: Tel: Mobile: The latest date you need your passport returned in time for your travel: Benin tourist visa checklist Filled
More informationThe use of prosecution history in post-grant patent proceedings
Question Q229 National Group: Denmark/Dänemark/Danemark Title: The use of prosecution history in post-grant patent proceedings Contributors: Ulla KLINGE, Peter-Ulrik PLESNER, Mikkel VITTRUP, Jakob KRAG
More informationLiability for contributory infringement of IPRs certain aspects of patent infringement
Question Q204P National Group: Japan Group Title: Liability for contributory infringement of IPRs certain aspects of patent infringement Contributors: Takeshi Aoki, Koji Akutsu, Katsumi Isogai, Yusuke
More informationB2B Misleading Marketing Practices Luc Hendrickx UEAPME Director Enterprise Policy and External Relations
B2B Misleading Marketing Practices Luc Hendrickx UEAPME Director Enterprise Policy and External Relations European Economic and Social Committee SMEs, Professions and Crafts Category 28 th June 2013 Brussels
More information* REPORT. EN United in diversity EN A7-0052/
EUROPEAN PARLIAMT 2009-2014 Session document 10.11.2009 A7-0052/2009 * REPORT on the initiative of the French Republic with a view to adopting a Council decision on the use of information technology for
More informationInjunctions in cases of infringement of IPRs. The Groups are invited to answer the following questions under their national laws:
Question Q219 National Group: Italy Title: Injunctions in cases of infringement of IPRs Contributors: Reporter within Working Committee: Lamberto Liuzzo Date: 5-4-2011 Questions I. Analysis of current
More informationREPORTS OF INTERNATIONAL ARBITRAL AWARDS RECUEIL DES SENTENCES ARBITRALES
REPORTS OF INTERNATIONAL ARBITRAL AWARDS RECUEIL DES SENTENCES ARBITRALES Giorgio Uzielli Case Decision No. 229 29 July 1963 VOLUME XVI pp. 267-271 NATIONS UNIES - UNITED NATIONS Copyright (c) 2006 GIORGIO
More informationPsychotropic Substances Act B.E (1975) BHUMIBOL ADULYADEJ, REX. Given on 4th January B.E. 2518; Being the 30th year of the present Reign.
Psychotropic Substances Act B.E. 2518 (1975) BHUMIBOL ADULYADEJ, REX. Given on 4th January B.E. 2518; Being the 30th year of the present Reign. His Majesty King Bhumibol Adulyadej is graciously pleased
More information2ND SESSION, 41ST LEGISLATURE, ONTARIO 66 ELIZABETH II, Bill 142. An Act to amend the Construction Lien Act. The Hon. Y. Naqvi Attorney General
2ND SESSION, 41ST LEGISLATURE, ONTARIO 66 ELIZABETH II, 2017 Bill 142 An Act to amend the Construction Lien Act The Hon. Y. Naqvi Attorney General Government Bill 1st Reading May 31, 2017 2nd Reading 3rd
More informationONTARIO REGULATION to be made under the
Disclaimer: This consultation draft is intended to facilitate dialogue concerning its contents. Should the decision be made to proceed with the proposal, the comments received during consultation will
More informationModèle de Contrat d Agent Commercial pour l Inde
Modèle de Contrat d Agent Commercial pour l Inde Modèle de Contrat d Agent Commercial utilisé lorsqu une société étrangère désigne un agent commercial en Inde afin que celui-ci fasse la promotion et vende
More informationStanding Committee on the Status of Women
Standing Committee on the Status of Women FEWO NUMBER 065 1st SESSION 41st PARLIAMENT EVIDENCE Thursday, March 21, 2013 Chair Ms. Marie-Claude Morin 1 Standing Committee on the Status of Women Thursday,
More informationLessons learnt 6 February 2015
Patent infringement Lessons learnt from patent case law in Europe in 2013 and 2014 Véron & Associés Seminar Paris Maison de la Recherche Sabine Agé Paris Lyon Patent infringement Bolar exemption (1/2)
More informationLiability for contributory infringement of IPRs certain aspects of patent infringement
Question Q204P National Group: The Netherlands Title: Liability for contributory infringement of IPRs certain aspects of patent infringement Contributors: John Allen, Klaas Bisschop, Arnout Gieske, Willem
More informationSIXTY-FOURTH LEGISLATURE OF THE STATE OF WYOMING 2018 BUDGET SESSION
AN ACT relating to controlled substances; creating an opioid addiction task force; specifying task force duties, membership and staffing; requiring coordination between the advisory council on palliative
More informationDRAFT OPINION. EN United in diversity EN. European Parliament 2016/0132(COD) of the Committee on Budgets
European Parliament 2014-2019 Committee on Budgets 2016/0132(COD) 24.1.2017 DRAFT OPINION of the Committee on Budgets for the Committee on Civil Liberties, Justice and Home Affairs on the proposal for
More informationBenin Business visa Application
Benin Business visa Application Please enter your contact information Name: Email: Tel: Mobile: The latest date you need your passport returned in time for your travel: Benin business visa checklist Filled
More informationELECTRICAL FIELD/ DOMAINE DE L ÉLECTRICITÉ
IPC/WG/21 MAINTENANCE PROJECT FILE/ DOSSIER DE PROJET MAINTENANCE ELECTRICAL FIELD/ DOMAINE DE L ÉLECTRICITÉ ORIGINAL: English/French DATE: 04.06.2009 WORLD INTELLECTUAL PROPERTY ORGANIZATION ORGANISATION
More informationCase Name: Lukacs v. Canada (Canadian Transportation Agency)
Page 1 Case Name: Lukacs v. Canada (Canadian Transportation Agency) Between Dr. Gabor Lukacs, Applicant, and Canadian Transportation Agency et al., Respondents, and The Privacy Commissioner of Canada,
More informationCorrigé du bac 2017 : Anglais LV1 Séries S-ES-L Polynésie
Corrigé du bac 2017 : Anglais LV1 Séries S-ES-L Polynésie BACCALAURÉAT GÉNÉRAL SESSION 2017 ANGLAIS LANGUE VIVANTE 1 Durée de l épreuve : 3 heures Séries ES et S coefficient : 3 Série L Langue vivante
More informationWeek 5 cumulative project: immigration in the French and Francophone world.
IPA Worksheet for Novice High French Students Theme : Immigration to the French Hexagon French 1103: An Accelerated Introduction to French in the World is designed for students with three to four years
More informationWELCOMING REMARKS. Sergio Balanzino. NATO Deputy Secretary General
WELCOMING REMARKS Sergio Balanzino NATO Deputy Secretary General It s a great pleasure to welcome you to the 1998 NATO Economics Colloquium. For over 25 years, this conference has brought together economic
More informationReport Germany to Question B
LIDC Congress Geneva 2016 Report Germany to Question B What rules should govern claims by suppliers about the national or geographic origin of their goods or services? Prof. Dr. Olaf Sosnitza 1. Do your
More information